Cerity Partners’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $53.4M | Sell |
1,250,901
-12,854
| -1% | -$698K | 0.06% | 247 |
|
|
2026
Q1 | $79.3M | Sell |
1,263,755
-1,769
| -0.1% | -$142K | 0.11% | 167 |
|
|
2025
Q4 | $121M | Buy |
1,265,524
+39,345
| +3% | +$3.86M | 0.18% | 117 |
|
|
2025
Q3 | $120M | Sell |
1,226,179
-75,325
| -6% | -$7.8M | 0.19% | 107 |
|
|
2025
Q2 | $140M | Buy |
1,301,504
+10,625
| +0.8% | +$1.08M | 0.25% | 88 |
|
|
2025
Q1 | $130M | Buy |
1,290,879
+653,370
| +102% | +$65.8M | 0.26% | 80 |
|
|
2024
Q4 | $55.9M | Sell |
637,509
-74,373
| -10% | -$6.55M | 0.12% | 155 |
|
|
2024
Q3 | $59.7M | Buy |
711,882
+80,334
| +13% | +$6.33M | 0.13% | 156 |
|
|
2024
Q2 | $48.6M | Sell |
631,548
-31,219
| -5% | -$2.29M | 0.13% | 157 |
|
|
2024
Q1 | $45.4M | Buy |
662,767
+111,346
| +20% | +$7.16M | 0.12% | 172 |
|
|
2023
Q4 | $31.9M | Buy |
551,421
+145,359
| +36% | +$7.76M | 0.1% | 182 |
|
|
2023
Q3 | $21.4M | Sell |
406,062
-75,018
| -16% | -$3.93M | 0.1% | 180 |
|
|
2023
Q2 | $26M | Buy |
481,080
+6,732
| +1% | +$352K | 0.1% | 192 |
|
|
2023
Q1 | $25.6M | Buy |
474,348
+25,967
| +6% | +$1.22M | 0.06% | 209 |
|
|
2022
Q4 | $20.7M | Buy |
448,381
+32,904
| +8% | +$1.42M | 0.13% | 162 |
|
|
2022
Q3 | $16.1M | Buy |
415,477
+815
| +0.2% | +$32.7K | 0.19% | 105 |
|
|
2022
Q2 | $15.5M | Buy |
414,662
+324,804
| +361% | +$13.2M | 0.17% | 122 |
|
|
2022
Q1 | $3.98M | Sell |
89,858
-3,141
| -3% | -$136K | 0.06% | 223 |
|
|
2021
Q4 | $3.95M | Buy |
92,999
+8,511
| +10% | +$358K | 0.06% | 229 |
|
|
2021
Q3 | $3.67M | Sell |
84,488
-3,282
| -4% | -$145K | 0.08% | 186 |
|
|
2021
Q2 | $3.75M | Sell |
87,770
-40,731
| -32% | -$1.71M | 0.08% | 184 |
|
|
2021
Q1 | $4.97M | Sell |
128,501
-17,598
| -12% | -$666K | 0.12% | 149 |
|
|
2020
Q4 | $5.25M | Buy |
146,099
+10,121
| +7% | +$365K | 0.17% | 120 |
|
|
2020
Q3 | $5.2M | Buy |
135,978
+90,010
| +196% | +$3.47M | 0.21% | 92 |
|
|
2020
Q2 | $1.61M | Buy |
45,968
+3,041
| +7% | +$110K | 0.09% | 150 |
|
|
2020
Q1 | $1.4M | Buy |
42,927
+11,458
| +36% | +$448K | 0.09% | 159 |
|
|
2019
Q4 | $1.42M | Sell |
31,469
-66,130
| -68% | -$2.77M | 0.07% | 200 |
|
|
2019
Q3 | $3.97M | Buy |
97,599
+39,233
| +67% | +$1.66M | 0.23% | 97 |
|
|
2019
Q2 | $2.51M | Sell |
58,366
-19,157
| -25% | -$737K | 0.16% | 133 |
|
|
2019
Q1 | $2.98M | Sell |
77,523
-48,217
| -38% | -$1.84M | 0.2% | 109 |
|
|
2018
Q4 | $4.44M | Buy |
125,740
+6,642
| +6% | +$241K | 0.3% | 75 |
|
|
2018
Q3 | $4.58M | Sell |
119,098
-5,505
| -4% | -$192K | 0.32% | 78 |
|
|
2018
Q2 | $4.08M | Sell |
124,603
-6,951
| -5% | -$210K | 0.3% | 84 |
|
|
2018
Q1 | $3.59M | Sell |
131,554
-7,702
| -6% | -$209K | 0.27% | 93 |
|
|
2017
Q4 | $3.45M | Buy |
139,256
+7,270
| +6% | +$201K | 0.23% | 99 |
|
|
2017
Q3 | $3.85M | Buy |
131,986
+39,022
| +42% | +$1.08M | 0.27% | 88 |
|
|
2017
Q2 | $3.94M | Sell |
92,964
-16,338
| -15% | -$434K | 0.33% | 67 |
|
|
2017
Q1 | $2.72M | Buy |
+109,302
| New | +$2.66M | 0.23% | 89 |
|
Other funds holding BSX
VCM
VPM
Cerity Partners's BSX Position: Q2 2026 in Review
Cerity Partners reduced its Boston Scientific (BSX) stake by 1% in Q2 2026, selling an estimated $698K and leaving 1,250,901 shares worth $53.4M. The position accounts for 0.06% of the portfolio, ranked #247.
Cerity Partners first reported a position in BSX in Q1 2017 and has held it in 38 quarters since. The position peaked at $140M in Q2 2025. 1,294 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Cerity Partners held 1,250,901 shares of Boston Scientific worth $53.4M as of Q2 2026.
- Cerity Partners sold 12,854 Boston Scientific shares in Q2 2026, an estimated $698K.
- Boston Scientific made up 0.06% of Cerity Partners's portfolio in Q2 2026, its #247 holding.
- Cerity Partners first reported a position in Boston Scientific in Q1 2017 and has held it in 38 quarters since.
- Cerity Partners's Boston Scientific position peaked at $140M in Q2 2025.
- 1,294 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.